COPENHAGEN, Denmark — Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421). The Company initiated its Phase 2 clinical study...
Latest News
PERTH, Australia – Lung cancer kills more people globally each year than any other type of cancer, however new Curtin University-led research has found less than five minutes of daily physical activity could be linked with prolonged life in people living with inoperable forms of the disease. The team from...
She is living her life to the fullest, even though she can’t walk or talk. Twelve-year-old Breanna Leatherwood of Tuscaloosa is one of about 50 females in Alabama known to have Rett syndrome, a neuro- developmental disorder that affects a gene on the X chromosome and occurs almost exclusively in...
SHANGHAI, China and SOUTH SAN FRANCISCO, Calif. — Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in...
SHANGHAI, China — Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by South Korean’s Ministry of Food and Drug Safety (MFDS) for the treatment of primary...
SHANGHAI, China — Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration (TFDA) for the treatment of primary immunoglobulin A...
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each worth $5,000, to cover a winning applicant’s...
Cambridge, MA – A surprising MIT study published in Nature at the end of 2016 helped to spur interest in the possibility that light flickering at the frequency of a particular gamma-band brain rhythm could produce meaningful therapeutic effects for people with Alzheimer’s disease. In a new review paper in the Journal of Internal...
Cambridge, UK – Pseudomonas aeruginosa – an environmental bacteria that can cause devastating multidrug-resistant infections, particularly in people with underlying lung conditions – evolved rapidly and then spread globally over the last 200 years, probably driven by changes in human behaviour, a new study has found. P. aeruginosa is responsible...
Budapest – Recent research suggests that the emergence of tuberculosis infection in human populations dates back tens of thousands of years earlier than previously known cases in the Middle East. In collaboration with an international research team, Hungarian researchers have edited and published a special issue of the journal Tuberculosis....